Close
Solutions
Online Inquiry

CONTACT US

USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
UK:167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Germany: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
UK: 44-207-097-1828
Fax: 1-631-207-8356
Email:

One-Stop CAR-NK Therapy Development

A new era of cancer immunotherapy has begun. Chimeric antigen receptor T (CAR-T) cells, which have been genetically engineered to recognize the CD-19 antigen of B cells, have been successfully treated in various clinical trials for relapsed and refractory B cell malignancies. However, this treatment has several disadvantages. Side effects such as cytokine toxicity, tumor lysis syndrome, effects on healthy tissues, B cell hypoplasia, and genotoxicity can be fatal.

To avoid these drawbacks, CAR technology is being applied to other immune cells, such as natural killer (NK) cells. Unlike T cells, NK cells can be more easily fine-tuned to prevent treatment-related toxicity and immune-mediated adverse events. NK cells have great clinical significance because they contribute to graft-vs-leukemia / graft-vs-tumor effect but are not responsible for graft-vs-host disease. NK cells can be generated from various sources, such as cord blood, bone marrow, human embryonic stem cells, and induced pluripotent stem cells.

CAR-NK vs CAR-T

Primary NK cells engineered to express CAR have potential advantages over CAR-T cells.

  • NK cells have spontaneous cytotoxic activity and can cause target cell death independent of tumor antigens, while T lymphocytes only kill their targets through CAR specific mechanisms. Therefore, NK cells will still be effective against tumor cells in the case of down-regulation of tumor cells that are trying to evade immune detection.
  • Primary human NK cells produce cytokines such as interferon gamma, interleukin 3, and granulocyte macrophage colony stimulating factor, which are different from the proinflammatory cytokines produced by T cells responsible for the onset of cytokine release syndrome.
  • A single NK cell can survive after contacting and killing multiple target cells, which may reduce the number of cells that require adoptive transfer, as opposed to T cells.
  • In addition, although the long-term persistence of CAR-T cells can maintain on-target and off-tumor toxicity, mature NK cells have a short lifespan and are expected to disappear after promoting their anti-cancer effects.

Therefore, NK cell lines are attractive for CAR cell therapy.

As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs masters the most advanced CAR technology. With state-of-art CAR development platforms and advanced technologies, Creative Biolabs is capable of offering a broad range of CAR-NK early development services, including CAR engineered T cell biomarker identification and selection, design, construction, and analysis.

One-Stop CAR-NK Therapy Development
Biomarker Identification & Selection
  • De novo discovery of potential cancer biomarkers by multiple gene and protein analysis technologies
  • Selection of the most suitable CAR-NK therapy targets with greater potency and lower toxicity
One-Stop CAR-NK Therapy Development
High Affinity ScFv Generation
  • In-house inescapable antibody sequence data base
  • A collection of over 6000 antibody products
  • Antibody discovery by hybridomas, mouse, rabbit and human library
  • ScFv sequencing and NGS of hybridomas or phage libary
  • ScFv affinity measurement and optimization
One-Stop CAR-NK Therapy Development
CAR-NK Vector Design and Construction
  • Design and construction of CARs of different generation
  • Smart™ CAR platform for the next generation CAR discovery
  • Customized lentiviral or retroviral CAR construction
One-Stop CAR-NK Therapy Development
Virus Packaging & CAR Gene Delivery
  • High titer transduction-ready pseudoviral particles produced by our cell manufacture platform
  • GMP virus manufacturing for clinical trials and applications
  • Strict quality control
  • Various transfection technology available
  • Transfection method tailored for different cell types
One-Stop CAR-NK Therapy Development
CAR-NK In Vitro Assay
  • CAR expression validation
  • CAR-NK cell proliferation
  • Multiplex cytokine screening
  • Cytotoxicity test against target cells
One-Stop CAR-NK Therapy Development
CAR-NK Preclinical In Vivo Assay
  • Construction of Xenograft Animal Model
  • Efficacy Test of CAR-NK cells
  • Viability and Bio-distribution Study of CAR-NK cells
  • Toxicity Evaluation of CAR-NK cells
  • GLP-compliant assays
One-Stop CAR-NK Therapy Development
CAR-T Clinical Trial
  • Study design and filing
  • Project management and execution
  • Data management and biostatistics
  • QA&QC

All services and products are only for lab research use, not for any clinical diagnosis or treatment.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.